Compare Cognizant Technology Solutions Corp (CTSH) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Danaher Corporation — how do they compare? Cognizant Technology Solutions Corp trades at $59.82 (market cap $27.03B), while Danaher Corporation trades at $217.43 (market cap $152.87B). The key difference: Danaher Corporation is far larger — about 5.7× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.2%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Danaher Corporation for 69 Days on average.
| CTSH | DHR | |
|---|---|---|
Market Cap | $27.03B | $152.87B |
Volume | 9,883,888 | 5,228,698 |
Sector | Technology | Health |
52-Week High | $86.70 | $242.05 |
52-Week Low | $38.73 | $161.91 |
Typical Hold Time | 57 Days | 69 Days |
Enterprise Value | $28.08B | $175.08B |
Dividend Yield | 2.2% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% with bearish technical signals despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 12.25 and EV/EBITDA of 6.52, while maintaining solid profitability with 10.26% net margin. Recent news highlights the company's AI transformation initiatives and recognition as a top employer, though Q2 2026 earnings missed expectations.
CTSH presents a compelling value opportunity with strong fundamentals and analyst consensus target of $64.25 (12.6% upside). Risks include IT spending pressures from AI disruption and competitive threats. The upcoming Q3 2026 earnings report on October 29, 2026 will be critical for validating the company's growth trajectory amid industry headwinds.
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
